g5 mobile sensor Search Results


g5 mobile sensor  (Dexcom Inc)
90
Dexcom Inc g5 mobile sensor
G5 Mobile Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g5 mobile sensor/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
g5 mobile sensor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
g4 ™ platinum/g5 ™ mobile sensors  (Dexcom Inc)
90
Dexcom Inc g4 ™ platinum/g5 ™ mobile sensors
G4 ™ Platinum/G5 ™ Mobile Sensors, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g4 ™ platinum/g5 ™ mobile sensors/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
g4 ™ platinum/g5 ™ mobile sensors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
g5 transcutaneous sensor  (Dexcom Inc)
90
Dexcom Inc g5 transcutaneous sensor
Participant characteristics
G5 Transcutaneous Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g5 transcutaneous sensor/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
g5 transcutaneous sensor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Participant characteristics

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Participant characteristics

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Total data collected during DG5 and EVS use and percentage of use when sensor was active

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Total data collected during DG5 and EVS use and percentage of use when sensor was active

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Glycemic control during EVS and DG5 sensor use

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Glycemic control during EVS and DG5 sensor use

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques: Standard Deviation